I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis

John Carroll

Editor & Founder

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Roche unruffled by China bill as it looks to grow roots in the region

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Following lower-than-expected profits, Evotec plans to cut costs, completes CEO search

FDA's biologics chief Peter Marks previews accelerated approval guidance

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

more like this

De­spite on­col­o­gy cut­backs, Sanofi isn’t out of the game yet with ear­ly as­sets

Roche un­ruf­fled by Chi­na bill as it looks to grow roots in the re­gion

Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Fol­low­ing low­er-than-ex­pect­ed prof­its, Evotec plans to cut costs, com­pletes CEO search

FDA's bi­o­log­ics chief Pe­ter Marks pre­views ac­cel­er­at­ed ap­proval guid­ance

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis

Despite oncology cutbacks, Sanofi isn’t out of the game yet with early assets

Roche unruffled by China bill as it looks to grow roots in the region

Drug and biotech companies join lobbying push on China bill as scrutiny of WuXi continues

Following lower-than-expected profits, Evotec plans to cut costs, completes CEO search

FDA's biologics chief Peter Marks previews accelerated approval guidance

Exclusive: In $1B+ bet on AI, biopharma heavyweights back new startup to upend drug R&D